Betta Pharmaceuticals announced that the BPI - 572,300 capsules declared by Hangzhou Jingyao Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, for use in phase I/II clinical studies on advanced solid tumor patients with specific RAS mutations have been reviewed and approved by the Australian Human Research Ethics Committee and completed the Australian Medicines Administration clinical trial registration. This is the company's first new drug approved for clinical trials in Australia.

Betta Pharmaceuticals announced that the BPI - 572,300 capsules declared by Hangzhou Jingyao Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, for use in phase I/II clinical studies on advanced solid tumor patients with specific RAS mutations have been reviewed and approved by the Australian Human Research Ethics Committee and completed the Australian Medicines Administration clinical trial registration. This is the company's first new drug approved for clinical trials in Australia.